1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Universal Ibogaine Inc.

Universal Ibogaine Inc.

IBO.V
Universal Ibogaine Inc.CA flagToronto Stock Exchange Ventures
0.01
CAD
+0.00
- -
1.56MMarket Cap
Universal Ibogaine Inc.
IBO.V
(Toronto Stock Exchange Ventures)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.01
Revenue per Share
- -
-0.04
-0.01
-0.01
-0.03
-0.03
-0.06
-0.01
-0.01
- -
Basic EPS, GAAP
- -
-0.03
-0.01
-0.01
-0.02
-0.03
-0.02
-0.01
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.02
0.01
- -
-0.01
0.01
- -
-0.01
-0.01
-0.01
Book Value per Share
- -
0.03
0.02
0.01
- -
0.02
0.02
0.01
- -
- -
Tangible Book Value per Share
- -
10
10
12
10
125
186
191
233
309
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
1
1
2
2
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-443.24
-199.1
-38.66
-34.25
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
-4
-10
-2
-2
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-980.22
-232.08
-88.01
-71.66
Profit Margin (%)
- -
- -
- -
- -
- -
- -
-1
-2
- -
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
1
3
2
LT Debt
- -
- -
- -
- -
- -
3
4
2
1
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-139.06
-71.01
- -
- -
- -
-1,312.72
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'25
ST Debt
- -
- -
1
LT Borrowings
2
2
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
309
309
309
Market Capitalization
3
6
8

Working Capital

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'25
Total Current Assets
1
- -
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
1
1
2
Payables & Accruals
1
1
1
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-13,264.21%
-43.42%
Free Cash Flow
- -
295.11%
-37.07%
Net Income, GAAP
- -
291.25%
-14.17%
Sales/Revenue/Turnover
- -
- -
126.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
1
1
2024
1
1
1
1
2
2025
- -
- -
1
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Initiator Pharma A/S (INIT.ST)
Horizon Space Acquisition II Corp. (SLBT)
Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ)
Polynovo Limited (CALZF)
Kiromic BioPharma, Inc. (KRBP)
CanSino Biologics Inc. (6185.HK)
Business
Universal Ibogaine Inc. operates as a life sciences firm dedicated to revolutionizing addiction recovery through advanced therapeutic modalities. The company is actively pursuing Health Canada approval for clinical trials investigating ibogaine, a natural psychoactive compound, as a medicalized treatment for opioid use disorder. Concurrently, it manages addiction treatment facilities in Canada, including the Kelburn Recovery Centre, which is being enhanced to integrate novel treatments beyond traditional methods. The firm's operational base is located in Calgary, Canada.